GlaxoSmithKline PLC - FTSE 100-listed pharmaceutical company - Submits biologics license application to US Food & Drug Administration for Priorix, and is seeking approval for use in immunisation against measles, mumps and rubella.
Priorix is currently licensed in more than 100 countries, including all countries in Europe, Canada, Australia and New Zealand.
"If approved, Priorix will increase the number of vaccine offerings from GSK against childhood
diseases in the US market and strengthen GSK's long-term commitment to prioritizing public health in the US," said Head of US Vaccines Judy Stewart.
Current stock price: 1,427.60 pence
Year-to-date change: up 6.4%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
